Clinical effectiveness and safety of TAZ/PIPC (YP-18) 4.5g for the prevention of infectious complication of prostate biopsy
Not Applicable
- Conditions
- Suspected prostate cancer
- Registration Number
- JPRN-UMIN000003228
- Lead Sponsor
- Department of Urology, Gifu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient who has allergy against the TAZ/PIPC or compounds of penicillins 2.Patient who has infectious mononucleosis 3.Others whom doctors in charge considered to be not apropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical effectiveness and safety of TAZ/PIPC (YP-18) 4.5g for the prevention of infectious complication of prostate biopsy.
- Secondary Outcome Measures
Name Time Method